Format

Send to

Choose Destination
Neurologia. 2017 Jan - Feb;32(1):1-5. doi: 10.1016/j.nrl.2014.09.007. Epub 2014 Nov 11.

Prevalence of myasthenia gravis in the Catalan county of Osona.

[Article in English, Spanish]

Author information

1
Servicio de Neurología, Consorci Hospitalari de Vic, Vic, Barcelona, España.
2
Servicio de Epidemiología Clínica e Investigación, Consorci Hospitalari de Vic, Vic, Barcelona, España. Electronic address: jaltimiras@chv.cat.
3
Servicio de Epidemiología Clínica e Investigación, Consorci Hospitalari de Vic, Vic, Barcelona, España.
4
Servicio de Medicina Interna, Consorci Hospitalari de Vic, Vic, Barcelona, España.
5
Servicio de Neurología, Clínica de Vic, Vic, Barcelona, España.
6
Unidad de Enfermedades Neuromusculares, Departamento de Neurología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.

Abstract

INTRODUCTION:

The reported prevalence of myasthenia gravis ranges between 5 and 24 cases per 100,000, and people over 65years account for less than 50% of all cases. The prevalence and clinical characteristics of myasthenia gravis in the county of Osona were studied in patients younger and older than 65.

METHODS:

The study draws from the county-based prospective myasthenia gravis register implemented by the Neurology Department at Hospital General de Vic in 1991.

RESULTS:

The prevalence of myasthenia gravis was 32.89×105 inhabitants (95%CI, 23.86-41.91). The standardized prevalence (European population) was 35.47×105 inhabitants (95%CI, 26.10-44.84). The ratio of women to men was 1.3. Overall, the group of patients older than 65 accounted for 62.75% of all cases. The prevalence of myasthenia gravis increased considerably in older age groups. No cases were registered among patients under 25years old, prevalence was 21.87×105 in the 25 to 64 age group, and prevalence in patients over 65 years increased to 122.35×105. The clinical characteristics prior to treatment and at the cut-off date are similar (P>.05) in patients younger than 65 and those aged 65 and older.

CONCLUSIONS:

These figures show the highest prevalence rate reported to date. This high prevalence is due to the rate observed among patients older than 65. These results provide a new warning that myasthenia gravis may be underdiagnosed in the elderly population.

KEYWORDS:

Ageing; Edad avanzada; Geriatric neurology; Immunosenescence; Miastenia gravis; Myasthenia gravis; Neuroepidemiology; Neuroepidemiología; Neurogeriatría; Prevalence; Prevalencia; Senescencia inmunológica

PMID:
25449965
DOI:
10.1016/j.nrl.2014.09.007
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Ediciones Doyma, S.L.
Loading ...
Support Center